Autopsy report · NCT00323791
Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Cause of deathSlow enrollment
“slow accrual”
Life of this trial
- Ran for about 1 year 4 months before it stopped.
- 100 participants planned (an estimate, not an actual count).
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Sponsor type
- University, hospital or other
- Conditions
- Kidney Cancer
- Interventions
- gemcitabine hydrochloride; imatinib mesylate; gene expression analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis
- Participants
- 100 (planned, not actual)
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.